PMID- 34337716
OWN - NLM
STAT- MEDLINE
DCOM- 20220304
LR  - 20220304
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 25
IP  - 14
DP  - 2021 Jul
TI  - Iguratimod attenuates general disease activity and improves lung function in 
      rheumatoid arthritis-associated interstitial lung disease patients.
PG  - 4687-4692
LID - 26379 [pii]
LID - 10.26355/eurrev_202107_26379 [doi]
AB  - OBJECTIVE: Iguratimod is a new kind of synthetic small molecule disease modified 
      anti-rheumatic drug with good efficacy for rheumatoid arthritis (RA) treatment; 
      meanwhile, it exhibits potency to alleviate alveolar inflammation and pulmonary 
      fibrosis. However, its application in RA interstitial lung disease (ILD) patients 
      is seldomly reported. Thus, the current study aimed to investigate the efficacy 
      and safety of iguratimod plus glucocorticoid/cyclophosphamide vs. 
      glucocorticoid/cyclophosphamide in treating RA-ILD patients. PATIENTS AND 
      METHODS: Totally 101 RA-ILD patients underwent glucocorticoid/cyclophosphamide 
      (Control group: n=61) or iguratimod plus glucocorticoid/cyclophosphamide 
      (Iguratimod group: n=40) treatment were analyzed. General inflammation, disease 
      activity, serum disease marker levels, high resolution lung computed tomography 
      (HRCT) score, lung function indexes were evaluated within 24-week (W) treatment. 
      RESULTS: No difference of baseline demographic or disease-related features was 
      observed between Iguratimod group and Control group. Iguratimod group showed 
      lower levels of CRP and ESR at W4, W12 and W24; as well as decreased DAS28 score, 
      rheumatoid factor and anti-cyclic citrullinate peptide antibody levels at W12 and 
      W24 compared to Control group. HRCT score showed no difference between Iguratimod 
      group and Control group at any time points. As to lung function indexes, forced 
      vital capacity percent predicted [FVC (% predicted)], carbon monoxide diffusion 
      capacity percent predicted [DLCO (%predicted)] and 6-minute-walk distance (6MWD) 
      were all higher in Iguratimod group compared with Control group at W4, W12 and 
      W24. Besides, no difference in adverse events was discovered between these two 
      groups. CONCLUSIONS: Iguratimod attenuates general inflammation, disease 
      activity, and improves lung function in RA-ILD patients.
FAU - Shu, P
AU  - Shu P
AD  - The Graduate School, Xuzhou Medical University, Xuzhou, Jiangsu, P.R. China. 
      yinguan2416643@163.com.
FAU - Shao, S-Q
AU  - Shao SQ
FAU - Cai, X-N
AU  - Cai XN
FAU - Zhou, D-M
AU  - Zhou DM
FAU - Ma, H
AU  - Ma H
FAU - Lu, L
AU  - Lu L
FAU - Yin, H-Q
AU  - Yin HQ
FAU - Yin, S-L
AU  - Yin SL
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Chromones)
RN  - 0 (Sulfonamides)
RN  - 4IHY34Y2NV (iguratimod)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/administration & dosage/*therapeutic use
MH  - Arthritis, Rheumatoid/diagnosis/*drug therapy
MH  - Chromones/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Lung Diseases, Interstitial/diagnosis/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Respiratory Function Tests
MH  - Sulfonamides/administration & dosage/*therapeutic use
MH  - Tomography, X-Ray Computed
MH  - Young Adult
EDAT- 2021/08/03 06:00
MHDA- 2022/03/05 06:00
CRDT- 2021/08/02 06:22
PHST- 2021/08/02 06:22 [entrez]
PHST- 2021/08/03 06:00 [pubmed]
PHST- 2022/03/05 06:00 [medline]
AID - 26379 [pii]
AID - 10.26355/eurrev_202107_26379 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2021 Jul;25(14):4687-4692. doi: 
      10.26355/eurrev_202107_26379.